Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years
- Authors:
- Jie Xu
- Lu Xie
- Xin Sun
- Sen Dong
- Xiaodong Tang
- Wei Guo
-
Affiliations: Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100034, P.R. China - Published online on: May 7, 2019 https://doi.org/10.3892/ol.2019.10328
- Pages: 348-358
This article is mentioned in:
Abstract
 |
 |
|
Jiang S, Wang G, Chen J and Dong Y: Comparison of clinical features and outcomes in patients with extraskeletal vs skeletal Ewing sarcoma: An SEER database analysis of 3,178 cases. Cancer Manag Res. 10:6227–6236. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 348:694–701. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrari S, Mercuri M, Rosito P, Mancini A, Barbieri E, Longhi A, Rimondini S, Cesari M, Ruggieri P, Di Liddo M and Bacci G: Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity. J Chemother. 10:484–491. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H and Craft A: Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 47:22–29. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter L, et al: Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's oncology group. Pediatr Blood Cancer. 51:334–338. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Stahl M, Ranft A, Paulussen M, Bölling T, Vieth V, Bielack S, Görtitz I, Braun-Munzinger G, Hardes J, Jürgens H and Dirksen U: Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 57:549–553. 2001. View Article : Google Scholar | |
|
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P and Stewart LA; PRISMA-P Group, : Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 4:12015. View Article : Google Scholar : PubMed/NCBI | |
|
Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, et al: Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 27:3148–3153. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dumont SN, Trent JC, Patel S, Araujo DM, Dumont AG and Benjamin RS: A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas. J Clin Oncol. 29:100642011. View Article : Google Scholar | |
|
Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, Provenzi M, Bertolini P, Paolucci P and Carli M: Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer. 106:703–707. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G and Cairo MS: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's cancer group (CCG) experience. Pediatr Blood Cancer. 44:338–347. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Owens C, Laurence V, Benboubker L, Defachelles AS, Cupissol D, Rubie H, Brisse H, Rey A, Ollivier L, Couanet D, et al: Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma. Cancer Chemother Pharmacol. 71:399–404. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Dileo P, Grosso F, Casanova M, Jimeno J, Marsoni S, Podda RS, Ferrari S, Bertulli R and Casali PG: Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy. J Clin Oncol. 25:100402007. | |
|
Zwerdling T, Krailo M, Monteleone P, Byrd R, Sato J, Dunaway R, Seibel N, Chen Z, Strain J and Reaman G; Children's Oncology Group, : Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: A report from the Children's oncology group. Cancer. 106:1821–1828. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Attia S, Bolejack V, Ganjoo KN, George S, Agulnik M, Rushing DA, Loggers ET, Livingston MB, Wrig JA, Chawla SP, et al: A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 35:110052017. View Article : Google Scholar | |
|
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA and Kurzrock R: Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 18:2625–2631. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC and Blaney SM: A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children's oncology group. Eur J Cancer. 48:579–585. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC and Blaney SM: Phase II trial of irinotecan in children with refractory solid tumors: A Children's oncology group study. J Clin Oncol. 25:4622–4627. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, et al: Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial. Lancet Oncol. 14:371–382. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, Doyle LA, Chen H and Blaney SM: Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the Children's oncology group. Pediatr Blood Cancer. 62:440–444. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Minard-Colin V, Ichante JL, Nguyen L, Paci A, Orbach D, Bergeron C, Defachelles AS, André N, Corradini N, Schmitt C, et al: Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma-a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). Eur J Cancer. 48:2409–2416. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jones RL, Ferrari S, Blay JY, Navid F, Lardelli P, Alfaro V, Siguero M, Soman N and Chawla SP: A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing family of tumors. Invest New Drugs. 32:171–177. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Duffaud F and Therasse P: New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer. 87:881–886. 2000.(In French). PubMed/NCBI | |
|
Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, et al: Measuring response in solid tumors: Comparison of RECIST and WHO response criteria. Jpn J Clin Oncol. 33:533–537. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer. 47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Palmerini E, Jones RL, Setola E, Picci P, Marchesi E, Luksch R, Grignani G, Cesari M, Longhi A, Abate ME, et al: Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients. Acta Oncol. 57:958–964. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E, Rodriguez-Galindo C and Wozniak W: Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 60:1621–1625. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kurucu N, Sari N and Ilhan IE: Irinotecan and temozolamide treatment for relapsed Ewing sarcoma: A single-center experience and review of the literature. Pediatr Hematol Oncol. 32:50–59. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S, et al: Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 17:1732–1742. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, et al: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 379:1879–1886. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xie L, Guo W, Wang Y, Yan T, Ji T and Xu J: Apatinib for advanced sarcoma: Results from multiple institutions' off-label use in China. BMC Cancer. 18:3962018. View Article : Google Scholar : PubMed/NCBI | |
|
Alcindor T: Response of refractory Ewing sarcoma to pazopanib. Acta Oncol. 54:1063–1064. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yamamoto Y, Nozawa M, Shimizu N, Minami T, Yoshimura K and Uemura H: Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. Int J Urol. 21:1183–1184. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Attia S, Okuno SH, Robinson SI, Webber NP, Indelicato DJ, Jones RL, Bagaria SP, Jones RL, Sherman C, Kozak KR, et al: Clinical activity of pazopanib in metastatic extraosseous Ewing sarcoma. Rare Tumors. 7:59922015. View Article : Google Scholar : PubMed/NCBI | |
|
Mori Y, Kinoshita S, Kanamori T, Kataoka H, Joh T, Iida S, Takemoto M, Kondo M, Kuroda J and Komatsu H: The successful treatment of metastatic extraosseous Ewing sarcoma with pazopanib. Intern Med. 57:2753–2757. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Italiano A, Penel N, Toulmonde M, Bompas E, Piperno-Neumann S, Pulido M, Entz-Werle N, Le Cesne A, Chevreau CM, Duffaud F, et al: LBA67-Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: A French Sarcoma Group (FSG)/US National Cancer Institute phase II collaborative study. From ESMO 2018 congress, Proffered Paper session. https://cslide.ctimeetingtech.com/library/esmo/browse/search/2AuE#2Ea3302NBOctober 19–2018 | |
|
Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI | |
|
Canu B, Fioravanti A, Orlandi P, Di Desidero T, Ali G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R and Bocci G: Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia. 13:217–229. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R and Kerbel RS: Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther. 9:996–1006. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, et al: Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med. 23:356–362. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kimura K, Yamano T, Igeta M, Imada A, Jihyung S, Babaya A, Hamanaka M, Kobayashi M, Tsukamoto K, Noda M, et al: UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan. Cancer Sci. 109:3934–3942. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
De Wit M, Boers-Doets CB, Saettini A, Vermeersch K, de Juan CR, Ouwerkerk J, Raynard SS, Bazin A and Cremolini C: Prevention and management of adverse events related to regorafenib. Support Care Cancer. 22:837–846. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, Infanger M and Wehland M: Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int J Mol Sci. 19(pii): E32582018. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y and Robles RL: A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol. 21:297–304. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB and Delord JP: A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs. 33:138–147. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Garofalo C, Mancarella C, Grilli A, Manara MC, Astolfi A, Marino MT, Conte A, Sigismund S, Carè A, Belfiore A, et al: Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. Mol Endocrinol. 26:1603–1616. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Manara MC, Landuzzi L, Nanni P, Nicoletti G, Zambelli D, Lollini PL, Nanni C, Hofmann F, Garcia-Echeverria C, Picci P and Scotlandi K: Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res. 13:1322–1330. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A and Peters S: Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tong M, Wang J, He W, Wang Y, Pan H, Li D and Zhang H: Predictive biomarkers for tumor immune checkpoint blockade. Cancer Manag Res. 10:4501–4507. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, et al: comprehensive analysis of hypermutation in human cancer. Cell. 171:1042–1056 e10. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, et al: The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 4:1326–1341. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sand LG, Szuhai K and Hogendoorn PC: Sequencing overview of ewing sarcoma: A journey across genomic, epigenomic and transcriptomic landscapes. Int J Mol Sci. 16:16176–16215. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Aras M, Erdil TY, Dane F, Gungor S, Ones T, Dede F, Inanir S and Turoglu HT: Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors. Nucl Med Commun. 37:9–15. 2016.PubMed/NCBI | |
|
Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, Ganjoo KN, von Mehren M, Chow WA, Loeb DM, et al: SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 122:868–874. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E and Faivre S: Alternative Response Criteria [Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors (RECIST)] versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncologist. 19:394–402. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Beaty O III, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, et al: A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's oncology group study. Pediatr Blood Cancer. 55:440–445. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Subbiah V, Sankhala KK, Ratan R, Garcia ES, Boni V, Gill T, Villalobos VM, Chawla SP, Lardelli P, Siguero M, et al: Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study. J Clin Oncol. 36:115192018. View Article : Google Scholar | |
|
Michelagnoli M, Whelan J and Forsyth S; OTIS Trial Management Group, Site Investigators, : A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. Pediatr Blood Cancer. 62:158–159. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC and Reaman G: Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: A Children's oncology group study. Pediatr Blood Cancer. 47:790–794. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fox E, Patel S, Wathen JK, Schuetze S, Chawla S, Harmon D, Reinke D, Chugh R, Benjamin RS and Helman LJ: Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 17:3212012. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, et al: Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: A report from the Children's oncology group. Clin Cancer Res. 16:750–754. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Grier HE and Stegmaier K; Children's Oncology Group, : Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's oncology group. Pediatr Blood Cancer. 52:324–327. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC and Blaney SM: Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: A Children's oncology group study. Pediatr Blood Cancer. 60:237–241. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ and Widemann BC: A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. Cancer Chemother Pharmacol. 80:645–652. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J and Chow WA: Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 30:547–552. 2010.PubMed/NCBI | |
|
Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM and Adamson PC: A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's oncology group study. Pediatr Blood Cancer. 50:254–258. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, et al: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 14:8132014. View Article : Google Scholar : PubMed/NCBI | |
|
University of Oxford: Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma. 2015.https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000616-28/resultsNovember 2–2018 | |
|
Children's Oncology Group, : Alisertib in treating young patients with recurrent or refractory solid tumors or leukemia. 2017.https://clinicaltrials.gov/ct2/show/results/NCT01154816November 2–2018 | |
|
Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, et al: Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 29:4534–4540. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, et al: Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 30:1849–1856. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, et al: R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: Results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol. 29:4541–4547. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, Monge OR, Lassaletta A, Boldrini E, Pápai Z, et al: A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatr Blood Cancer. 63:1761–1770. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, et al: Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: A report from the Children's oncology group. J Clin Oncol. 30:256–262. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R and Grebennik DO: An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 49:3219–3228. 2013. View Article : Google Scholar : PubMed/NCBI |
